2020
Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies
Olamiju B, Bhullar S, Coleman EL, Leventhal JS. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. Journal Of The American Academy Of Dermatology 2020, 84: 806-808. PMID: 32526318, DOI: 10.1016/j.jaad.2020.06.010.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAdrenergic beta-AntagonistsAgedAngiolymphoid Hyperplasia with EosinophiliaAnti-Bacterial AgentsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCryotherapyErbB ReceptorsFemaleHead and Neck NeoplasmsHumansLung NeoplasmsMaleMiddle AgedParonychiaProtein Kinase InhibitorsRetrospective StudiesSeverity of Illness IndexSilver NitrateTimololTreatment Outcome
2019
Pruritic reticulation: don't ‘fiddle’ around
Salam A, Peleva E, Cowper SE, Leventhal JS. Pruritic reticulation: don't ‘fiddle’ around. Clinical And Experimental Dermatology 2019, 45: 501-504. PMID: 31762054, DOI: 10.1111/ced.14135.Peer-Reviewed Case Reports and Technical Notes
2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. Journal Of The American Academy Of Dermatology 2015, 73: 645-654. PMID: 26259990, DOI: 10.1016/j.jaad.2015.06.060.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAminoquinolinesCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImiquimodInjections, IntralesionalInterleukin-2MaleMelanomaNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRetinoidsRetrospective StudiesRisk AssessmentSkin NeoplasmsTreatment OutcomeConceptsIntralesional IL-2Cutaneous melanoma metastasesCutaneous metastatic melanomaIL-2Topical imiquimodMetastatic melanomaMelanoma metastasesCase seriesUS National Comprehensive Cancer Network guidelinesCommon treatment-related adverse eventsResponse rateNational Comprehensive Cancer Network guidelinesTreatment-related adverse eventsComplete response rateRetrospective case seriesPromising therapeutic optionLocal response rateAdverse eventsRetrospective reviewSurgical excisionNetwork guidelinesTherapeutic optionsCombination therapyBiopsy specimensRetinoid cream